Drug Profile
Idasanutlin - Roche
Alternative Names: RG-7388; RO-5503781Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Mayo Clinic; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; University of Glasgow
- Class Aminobenzoic acids; Antineoplastics; Halogenated hydrocarbons; Pyrrolidines; Small molecules
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia
- Phase II Solid tumours
- Phase I/II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Neuroblastoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
- Preclinical Glioblastoma; Rhabdoid tumour
- No development reported Cancer; Essential thrombocythaemia
- Discontinued Polycythaemia vera
Most Recent Events
- 11 Oct 2023 Preclinical trials in Rhabdoid tumour in USA (PO) before October 2023
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Rhabdoid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 19 Jul 2023 St. Jude Children's Research Hospital plans a phase I trial for Rhabdoid-tumour (Combination therapy, Second-line or greater therapy, In Children, In Adults) in the US (PO) (NCT05952687)